Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

4 terminated/withdrawn out of 6 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05409378Not ApplicableWithdrawn

HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

Role: lead

NCT02799823Not ApplicableTerminated

Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility Trial

Role: lead

NCT02838680Not ApplicableCompleted

Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Feasibility Trial CANADA

Role: lead

NCT02157142Not ApplicableCompleted

HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON

Role: lead

NCT03805711Not ApplicableTerminated

HLT Meridian Valve CE Mark Trial

Role: lead

NCT02159794Not ApplicableWithdrawn

HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON CANADA

Role: lead

All 6 trials loaded